Astra Zeneca reported that a blood pressure drug showed positive results.
The BaxHTN late stage trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure, compared with placebo.
AstraZeneca stock has risen about 24% in 2025
Results were seen in patients with hard-to-control hypertension who received baxdrostat or placebo on top of standard of care.
The data were presented last week at the European Society of Cardiology (ESC) Congress 2025 and also simultaneously published in the New England Journal of Medicine.
Results were consistent across both uncontrolled and treatment-resistant subgroups.
Baxdrostat was generally well tolerated with no unanticipated safety findings. The safety profile of baxdrostat was consistent with its mechanism of action, and most adverse events were mild.
AstraZeneca acquired the drug in a $1.3 billion purchase of CinCor in 2023. (See related story).
Sharon Barr, executive vice president, BioPharmaceuticals R&D, said: “The BaxHTN Phase III results demonstrate baxdrostat’s potential in tackling one of the toughest challenges in cardiovascular care, which is hypertension that is hard to control despite multiple therapies. We look forward to advancing our regulatory filings for baxdrostat with health authorities in the months ahead, in addition to rapidly progressing a robust clinical development program across indications where aldosterone plays a key role, including chronic kidney disease and heart failure prevention.”
There are 1.3 billion people worldwide living with hypertension.1 In the US, approximately 50% of patients living with hypertension on multiple treatments do not have their blood pressure under control.
A large meta-analysis found that lowering systolic blood pressure by 10 mmHg can reduce the risk of major adverse cardiovascular events by around 20%.
Baxdrostat targets one of the hormones driving elevated blood pressure and increased cardiovascular and kidney risk.
It is currently being investigated in clinical trials enrolling more than 20,000 patients globally.
AstraZeneca operates a U.S. headquarters, logistics and manufacturing operations in northern Delaware and employs 1,600.
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.